Methods of inducing tolerance and reducing adverse reactions to one or more food allergens
The use of pharmaceutical compositions with controlled doses of peanut allergens for oral mucosal delivery addresses the limitations of current immunotherapy treatments by increasing tolerance and reducing adverse reactions in individuals with peanut allergy.
WO2025080707A1 Publication Date: 2025-04-17INTROMMUNE THERAPEUTICS INC
4 Cites 0 Cited by
Patent Information
- Application Number
- PCT/US2024/050562
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-10-10
- Filing Date
- 2024-10-09
- Publication Date
- 2025-04-17
AI Technical Summary
Technical Problem
Current immunotherapy treatments for food allergies, particularly peanut allergy, have insufficient success rates and are often accompanied by adverse side effects, necessitating the development of novel therapies that promote immune tolerance while reducing adverse reactions.
Method used
The development of pharmaceutical compositions comprising one or more peanut allergens, administered in controlled doses for oral mucosal delivery, to increase tolerance and reduce the risk of adverse reactions in individuals with peanut allergy.
Benefits of technology
The proposed method effectively increases tolerance to peanut allergens, reducing the severity and risk of adverse reactions, thereby improving the quality of life for individuals with peanut allergy.
✦ Generated by Eureka AI based on patent content.
Abstract
Provided are compositions comprising one or more allergens as well as methods of using the same to increase tolerance and / or reduce adverse reactions to one or more allergens. In some embodiments, provided are compositions comprising one or more peanut allergens and methods of using the same to increase tolerance to and / or reduce adverse reactions to one or more peanut allergens.
Need to check novelty before this filing date? Find Prior Art